Beauty

Shiseido to sell Chinese Aupres subsidiary to IDG Capital-led consortium

The binding deal covers the Aupres maker’s Beijing factory and includes IP licensing and interim supply support for the new owners.

Ingrid LindqvistNovember 19, 20265 min read2 views

An unbranded skincare bottle rests between a cosmetics laboratory bench and a boardroom table, with a factory silhouette and abstract digital network in the background.

Shiseido has signed a binding agreement to sell Shiseido Liyuan Cosmetics (SLC), the Chinese subsidiary that makes and sells the Aupres brand, to an investor consortium led by Hong Kong-headquartered private equity firm IDG Capital. Financial terms were not disclosed. The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China.

Strategy and rationale

The transaction is part of Shiseido’s effort to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. The Japanese cosmetics group said it wants to focus management resources on areas where it “enjoys the greatest competitive advantage,” while pursuing sustainable growth and stronger competitiveness in China. According to Shiseido, SLC requires continued investment in product innovation and digital capabilities; divesting the business is intended to let the group concentrate on priority brands and higher-growth opportunities.

Shiseido described China as a strategically important and attractive, dynamic market where the competitive landscape is changing amid rapid e-commerce expansion, shifts in consumer behavior and the emergence of diverse market participants.

Joint venture history and ownership

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. It has sold the C-beauty brand Aupres since 1994. With the joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership before the sale.

Under the sale, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles. A limited partnership enterprise established mainly by SLC’s new management team will hold the remaining 5%. The deal includes SLC’s Beijing factory and production equipment. Shiseido said it believes independent operation under IDG will support SLC’s sustainable growth and brand value.

Handover arrangements

To support a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, it will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. Shiseido said the remaining collaboration is meant to maintain SLC’s innovation capabilities, product quality and business continuity.

Profit recovery context

The divestment follows Shiseido’s report of a 124.3% increase in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales rose 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million) on the back of those results.